Multifaceted intervention of assessment, education, and feedback increases likelihood of triple prescription fourfold over usual care<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 14, 2023 (HealthDay News) — A coordinated, multifaceted intervention increases prescription of three groups of evidence-based therapies in adults with type 2 diabetes and atherosclerotic cardiovascular disease (CVD), according to a study published online March 6 in the Journal of the American Medical Association<\/em> to coincide with the annual meeting of the American College of Cardiology, held from March 4 to 6 in New Orleans.<\/p>\n Neha J. Pagidipati, M.D., M.P.H., from the Duke Clinical Research Institute in Durham, North Carolina, and colleagues assessed the effect of a coordinated, multifaceted intervention of assessment, education, and feedback versus usual care on the proportion of adults with type 2 diabetes and atherosclerotic CVD prescribed all three groups of recommended, evidence-based therapies (high-intensity statins, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers [ACEIs or ARBs], and sodium-glucose cotransporter 2 inhibitors and\/or glucagon-like peptide 1 receptor agonists [SGLT2 inhibitors and\/or GLP-1RAs]). The analysis included 1,049 participants treated at 43 U.S. cardiology clinics (July 2019 through May 2022).<\/p>\n The researchers found that patients in the intervention group were more likely to be prescribed all three therapies (37.9 percent) versus individuals in the usual-care group (14.5 percent; adjusted odds ratio, 4.38) and were more likely to be prescribed each of the three therapies (adjusted odds ratios, 1.73, 1.82, and 3.11 for high-intensity statins, ACEIs or ARBs, and SGLT2 inhibitors and\/or GLP-1RAs, respectively). No changes in atherosclerotic CVD risk factors were seen with the intervention.<\/p>\n An absolute increase of 23.4 percent in prescriptions for all three recommended therapies in the intervention group versus the usual-care group, which was more than twice the improvement the trial was designed to detect, is clinically meaningful and, based on clinical trial evidence for these therapies, should result in a substantial improvement in patient outcomes over time, the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n